Should J&J’s Nipocalimab SLE Win and OTTAVA Robot Push Require Action From Johnson & Johnson (JNJ) Investors?

In early January 2026, Johnson & Johnson reported that nipocalimab (Imaavy) met primary and key secondary endpoints in the ...
Lupus Foundation of America

Phase 2b JASMINE trial of nipocalimab demonstrates positive results for treatment of systemic lupus erythematosus

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...
Applied Clinical Trials Online

Nipocalimab Delivers Positive Phase IIb Results in JASMINE SLE Trial

The JASMINE trial showed nipocalimab's efficacy in SLE, meeting primary and secondary endpoints, including steroid sparing ...

J&J succeeds in mid-stage trial for SLE therapy

Johnson & Johnson (JNJ) announced on Tuesday that nipocalimab, its experimental therapy for an autoimmune condition called ...
European Medical Journal

Key Risk Factors for Cerebral Small Vessel Disease in SLE

New data identify age, anti-β2GP1 antibodies, and low C3 as key risk factors for cerebral small vessel disease in systemic ...
Healio

SLE linked to increased risk for 16 cancers, decreased risk for melanoma

Systemic lupus erythematosus is associated with an increased risk for 16 cancers, including Hodgkin’s and non-Hodgkin’s lymphoma, leukemia and multiple myeloma, but a decreased risk for prostate ...